+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

2026 Scholars Program

Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) seeks proposals for the MMRF 2026 Scholars Program. The goal of this initiative is to attract and fund exceptional investigators while broadening participation among researchers whose communities, programs, and resources perspectives better reflect the demographic diversity of the real-world multiple myeloma patient population.

Applicants for the MMRF Scholars program must hold a Ph.D., M.D. or equivalent degree(s) - or are planning to defend their PhD within 12 months of the application date - and may not hold a title higher than assistant professor or equivalent at a US institution at the time of the award. Applicants must propose a clinical, translational, or basic science project relevant to the field of multiple myeloma. The Scholar program will provide up to $400,0000 of financial support over four (4) years ($100,000/year) to successful applicants.

Black/African American applicants with a strong interest in the multiple myeloma patient population are strongly encouraged to apply.

Key Dates:

• 04/06/2026 - Request for Applications (RFA) issued

• 06/30/2026 - Deadline for Submission of Applications

• 08/14/2026 - Applicant notification

Funding:

The funding period is four (4) years. The MMRF will provide $100,000 annually. Up to 75% of the funding may be used for salary support for the awardee. Allowable costs include laboratory direct costs, computer hardware and software, and publication costs. Salary support for the mentor or laboratory personnel such as technicians are not allowed. Funding will be completed at the end of four years or when the Scholar transitions to Associate Professor or leaves academia, whichever comes first.

AI Based Application Success Predictor

1. Strong relevance to multiple myeloma

The most competitive applications directly address:

multiple myeloma biology
smoldering multiple myeloma
MGUS
relapse and refractory disease
disease progression
minimal residual disease (MRD)
myeloma genomics
plasma-cell biology
high-risk multiple myeloma

MMRF requires funded projects to be directly relevant to multiple myeloma or its precursor conditions.

2. Clear translational and clinical impact

One of the strongest predictors of success is potential to:

improve treatment response
identify therapeutic targets
improve risk stratification
enable precision medicine
improve outcomes in high-risk disease
accelerate movement into clinical trials

MMRF strongly prioritizes research that can move rapidly from discovery toward patient benefit.

3. Innovation and novel therapeutic discovery

Highly competitive applications often involve:

novel drug targets
resistance mechanisms
immunotherapy approaches
cell therapies
antibody-based strategies
AI or computational myeloma biology
biomarker discovery

Projects proposing new biological insights or next-generation therapeutic strategies tend to score especially well.

4. Strong preliminary or proof-of-concept data

Successful applications usually include:

pilot genomic findings
feasibility studies
biomarker data
translational validation evidence
preclinical therapeutic data

MMRF fellowships can support early-stage work, but strong feasibility evidence substantially increases reviewer confidence.

5. Focus on high-risk disease and relapse

Particularly competitive projects often address:

high-risk newly diagnosed myeloma
early relapse biology
resistant disease
clonal evolution
progression from smoldering myeloma to active disease

Recent MMRF Myeloma Accelerator Challenge grants specifically focused on high-risk myeloma and disease progression.

6. Strong multidisciplinary collaboration

High-scoring projects frequently involve:

hematologists
medical oncologists
translational scientists
genomic researchers
immunologists
computational biologists
bioinformaticians

MMRF increasingly supports multicenter collaborative networks rather than isolated projects.

7. Strong investigator track record or early-career potential

Important predictors include:

prior myeloma publications
hematologic malignancy expertise
translational productivity
strong mentor support
future leadership potential in myeloma research

For Scholars and Fellowship programs, early-career development is a major focus.

8. Health equity and diversity relevance

A distinctive recent MMRF priority includes:

disparities in myeloma outcomes
Black patient populations
access-to-care inequities
inclusive clinical research participation

The MMRF Scholars Program explicitly highlights meaningful connections to communities disproportionately affected by multiple myeloma.

9. Potential to generate future large-scale studies or trials

Reviewers favor projects likely to:

support multicenter trials
generate NIH/NCI funding
create publishable high-impact data
feed into MMRF clinical networks
improve personalized treatment strategies

MMRF funding is often catalytic seed funding for larger translational programs.

10. Strong use of molecular and clinical data

Projects leveraging:

genomics
proteomics
multi-omics
clinical registries
molecular profiling
biomarker-driven patient stratification

are especially competitive because MMRF has invested heavily in myeloma data platforms and precision-medicine infrastructure.

Common Reasons for Rejection

Frequent reviewer concerns include:

weak myeloma specificity
insufficient translational relevance
limited innovation
poor feasibility
inadequate preliminary evidence
unclear clinical application
weak collaborative structure
overly broad scope

Specialties

Clinical Trials

Others

Eligibility Requirements

Applications for the MMRF 2026 Scholars Program are requested from clinical and/or laboratory investigators at academic, not-for-profit, institutions in the United States. Researchers who either hold a Ph.D., M.D. or equivalent degree(s), or are planning to defend their PhD within 12 months of the application date are invited to apply. The Multiple Myeloma Research Foundation will not deny the benefits described in the request to individuals based on race, ethnicity, gender, sex, sexual orientation, age, religion, national origin, or other protected status under federal or state law.

The following conditions must be met by all applicants:

• Applicant proposal must be a clinical, translational, or basic science investigation relevant to the field of multiple myeloma. The proposal is not required to have a specific diversity, equity, and inclusion focus. As with other MMRF supported research, a diversity plan for appropriate patient population representation in clinical or laboratory research is required.

• Applicants must have a research mentor in multiple myeloma or related field who will provide a suitable research environment, guidance on study conduct and career development.

• The MMRF Scholars program is intended for early career scientists and clinicians. Applicants must have obtained their highest degree within 10 years of the application date.

• Applicants and their research must be based at an academic, not-for-profit institution in the United States.

• Applicants may not hold a position higher than Assistant Professor.

Sponsor Details

Sponsor Institute/Organizations: Multiple Myeloma Research Foundation

Sponsor Type: Corporate/Non-Profit

Address: 383 Main Avenue, 7th Floor Norwalk, CT 06851

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity